DD Support Board and Research Team

[elbiatcho1]

They're still in recruiting status.

Locations
United States, South Carolina
ITOR/GHS Recruiting
Greenville, South Carolina, United States, 29605
Contact: Lisa Johnson, RN 864-455-3600 [e-mail]
Contact: Jill Cantrell, RN 8644553600 [e-mail]

Not even close to making the endpoint time.

Study Start Date: February 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

The dosing schedule to be used in this trial is designed to evaluate, in increments, the safety and tolerability of Prolanta over this 90 day cycle. Subjects will be assessed for antibody presence throughout the study, initially on a weekly basis and then bi-weekly. Subjects will be initially dosed for 28 days followed by a safety assessment period, and then continue for an additional 56 days if no toxicities are observed.

Moot point talking about patients if the company can't find any.